CNS (CNS) Stock Analysis

Verdict: AVOID

Premium P/E of 22x faces earnings misses and 6 analyst sell ratings, offset by a 4.0% dividend yield and robust 31% operating margins.

Investment score: 37/100

The model recommends avoiding CNS stock due to a rich valuation (P/E 22.05x vs peer median 11.34x), three consecutive quarterly EPS misses, and persistent sell sentiment from institutional analysts.

Peers

PeerP/EP/BP/SEV/EBITDAROIC %Net margin %
MAIN11.341.637.4717.000.65
HLNE13.564.005.819.260.32
OTF8.170.653.5617.860.27
FHI10.423.262.227.530.21
AB10.502.669.629.620.91

View the full interactive analysis